GlaxoSmithKline plc (LSE: GSK) and Theravance, Inc. (NASDAQ: THRX) today announced that the US Food and Drug Administration (FDA) has approved BREO® ELLIPTA® (fluticasone furoate/vilanterol [FF/VI]) ...

DUBLIN--(BUSINESS WIRE)--The "Drug Overview: Breo Ellipta" report has been added to ResearchAndMarkets.com's offering. Breo Ellipta (GlaxoSmithKline/Innoviva) is a combination of fluticasone furoate ...

The U.S. Food and Drug Administration on Thursday approved the sale of Breo Ellipta as a once-daily treatment for asthma in patients aged 18 and older, GlaxoSmithKline and Theravance Inc said. The FDA ...

The US Food and Drug Administration (FDA) has approved the combination of fluticasone furoate/vilanterol (Breo Ellipta, GlaxoSmithKline/Theravance) for the once-daily ...

DUBLIN--(BUSINESS WIRE)--The "Breo Ellipta" report has been added to ResearchAndMarkets.com's offering. Breo Ellipta (GlaxoSmithKline/Innoviva) is a combination of fluticasone furoate and vilanterol ...

GAITHERSBURG, Md. — Two FDA advisory committees today voted 16-4 in favor of approving Breo Ellipta for the treatment of asthma in individuals aged 18 years and older. However, the committee members ...

Dublin, Oct. 02, 2023 (GLOBE NEWSWIRE) -- The "Global BREO Ellipta Drugs Market Report and Forecast 2023-2031" report has been added to ResearchAndMarkets.com's offering. The global BREO ellipta drugs ...

BREO ELLIPTA (fluticasone furoate and vilanterol) Inhalation Powder Breo Ellipta (fluticasone furoate/vilanterol; GlaxoSmithKline and Theravance) has been made available for chronic obstructive ...

LONDON and SAN FRANCISCO, April 30, 2015 /PRNewswire/ -- GlaxoSmithKline plc (LSE: GSK) and Theravance, Inc. (NASDAQ: THRX) today announced that the US Food and Drug Administration (FDA) has approved ...

Please provide your email address to receive an email when new articles are posted on . The FDA on Thursday approved Breo Ellipta for the once-daily treatment of asthma in adults, according to a ...